Replimune Group, Inc.

NasdaqGS REPL

Replimune Group, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 111.34 M

Replimune Group, Inc. Net Cash Used Provided By Financing Activities is USD 111.34 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -59.20% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Replimune Group, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 272.90 M, a 516.41% change year over year.
Replimune Group, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 44.27 M, a -83.31% change year over year.
Replimune Group, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 265.25 M, a 32.71% change year over year.
Replimune Group, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 199.88 M, a 1,906.39% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: REPL

Replimune Group, Inc.

CEO	Dr. Sushil Patel Ph.D.
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive
Employees	331
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years